RYBELSUS

Clinical safety rating: caution

Comprehensive clinical and safety monograph for RYBELSUS (RYBELSUS).

How it works

Glucagon-like peptide-1 (GLP-1) receptor agonist; increases insulin secretion, decreases glucagon secretion, slows gastric emptying, and promotes satiety.

What the body does with it

Metabolism	Metabolized via proteolytic cleavage by general proteases, not primarily via CYP450 enzymes.
Excretion	Primarily eliminated via degradation by general proteolysis; intact peptide is not excreted renally or hepatobiliary. The degradation products are eliminated via renal and fecal routes. Approximately 60-70% of the dose is recovered in urine (as metabolites) and 30-40% in feces (as metabolites).
Half-life	Terminal elimination half-life is approximately 1 week (168 hours) after multiple doses due to absorption-rate-limited elimination. This supports once-weekly dosing, with steady state reached after 4-5 weeks.
Protein binding	Approximately 99% bound to albumin.
Volume of Distribution	Approximately 19 L (0.25 L/kg, assuming 75 kg) indicating distribution primarily into extracellular fluid.
Bioavailability	Subcutaneous bioavailability is approximately 89%.
Onset of Action	Peak glucose reductions are observed within 2-3 weeks of once-weekly subcutaneous administration, but initial glucose lowering begins within 1 week.
Duration of Action	Duration of action is approximately 1 week, consistent with once-weekly dosing. Clinical glucose-lowering effect is maintained over the full dosing interval with no loss of efficacy at end of week.

Classification & Brands

Action Class

Insulin Secretogogues: GLP-1 agonists

Dosing & administration

Initial: 3 mg orally once daily for 30 days; then increase to 7 mg orally once daily. If additional glycemic control needed, may increase to 14 mg orally once daily after at least 30 days on 7 mg.

Dosage form	TABLET
Renal impairment	No dose adjustment required for mild to moderate renal impairment (eGFR >=30). Not recommended for use in severe renal impairment (eGFR <30) or end-stage renal disease.
Liver impairment	No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C); use with caution.
Pediatric use	Safety and efficacy not established in pediatric patients under 18 years; no recommended dose.
Geriatric use	No dose adjustment required based on age. Consider renal function and potential for increased sensitivity; start at low dose and titrate gradually.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for RYBELSUS (RYBELSUS).

Breastfeeding	No data on presence in human milk; effects on breastfed infant unknown. M/P ratio not available. Semaglutide is excreted in rat milk. Use caution; prolonged half-life (1 week) suggests potential accumulation.
Teratogenic Risk	Risk cannot be ruled out (FDA Category C). First trimester: Limited human data; animal studies show embryo-fetal toxicity at exposures 0.6-23 times human exposure. Second/Third trimester: Not studied; potential for fetal harm due to maternal weight loss and malnutrition.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

Risk of thyroid C-cell tumors. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Personal or family history of medullary thyroid carcinoma","Multiple Endocrine Neoplasia syndrome type 2","History of serious hypersensitivity reaction to semaglutide or any product components"]

Clinical Precautions

Precautions

["Acute pancreatitis","Acute kidney injury","Hypoglycemia when used with insulin or insulin secretagogues","Diabetic retinopathy complications in clinical trials","Severe gastrointestinal adverse reactions","Hypersensitivity reactions","Risk of thyroid C-cell tumors"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

RYBELSUS

Clinical safety rating: caution

Comprehensive clinical and safety monograph for RYBELSUS (RYBELSUS).

How it works

Glucagon-like peptide-1 (GLP-1) receptor agonist; increases insulin secretion, decreases glucagon secretion, slows gastric emptying, and promotes satiety.

What the body does with it

Metabolism	Metabolized via proteolytic cleavage by general proteases, not primarily via CYP450 enzymes.
Excretion	Primarily eliminated via degradation by general proteolysis; intact peptide is not excreted renally or hepatobiliary. The degradation products are eliminated via renal and fecal routes. Approximately 60-70% of the dose is recovered in urine (as metabolites) and 30-40% in feces (as metabolites).
Half-life	Terminal elimination half-life is approximately 1 week (168 hours) after multiple doses due to absorption-rate-limited elimination. This supports once-weekly dosing, with steady state reached after 4-5 weeks.
Protein binding	Approximately 99% bound to albumin.
Volume of Distribution	Approximately 19 L (0.25 L/kg, assuming 75 kg) indicating distribution primarily into extracellular fluid.
Bioavailability	Subcutaneous bioavailability is approximately 89%.
Onset of Action	Peak glucose reductions are observed within 2-3 weeks of once-weekly subcutaneous administration, but initial glucose lowering begins within 1 week.
Duration of Action	Duration of action is approximately 1 week, consistent with once-weekly dosing. Clinical glucose-lowering effect is maintained over the full dosing interval with no loss of efficacy at end of week.

Classification & Brands

Action Class

Insulin Secretogogues: GLP-1 agonists

Dosing & administration

Initial: 3 mg orally once daily for 30 days; then increase to 7 mg orally once daily. If additional glycemic control needed, may increase to 14 mg orally once daily after at least 30 days on 7 mg.

Dosage form	TABLET
Renal impairment	No dose adjustment required for mild to moderate renal impairment (eGFR >=30). Not recommended for use in severe renal impairment (eGFR <30) or end-stage renal disease.
Liver impairment	No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C); use with caution.
Pediatric use	Safety and efficacy not established in pediatric patients under 18 years; no recommended dose.
Geriatric use	No dose adjustment required based on age. Consider renal function and potential for increased sensitivity; start at low dose and titrate gradually.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for RYBELSUS (RYBELSUS).

Breastfeeding	No data on presence in human milk; effects on breastfed infant unknown. M/P ratio not available. Semaglutide is excreted in rat milk. Use caution; prolonged half-life (1 week) suggests potential accumulation.
Teratogenic Risk	Risk cannot be ruled out (FDA Category C). First trimester: Limited human data; animal studies show embryo-fetal toxicity at exposures 0.6-23 times human exposure. Second/Third trimester: Not studied; potential for fetal harm due to maternal weight loss and malnutrition.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

Risk of thyroid C-cell tumors. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Personal or family history of medullary thyroid carcinoma","Multiple Endocrine Neoplasia syndrome type 2","History of serious hypersensitivity reaction to semaglutide or any product components"]